CTN: Northern New England Node

CTN：新英格兰北部节点

• 批准号: 7685080
• 负责人: Roger D. Weiss
• 金额: $ 65.99万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7685080
• 关键词: Adherence; Adopted; Arts; Attention deficit hyperactivity disorder; Caring; Clinical; Clinical Trials Network; Communities; Dependence; Development; Drug abuse; Evidence based practice; Funding; HIV; Health Personnel; Intervention; Lead; Leadership; Life; Maintenance; Methadone; Mission; National Institute of Drug Abuse; New England; Numbers; Opioid Analgesics; Participant; Patients; Performance; Pharmaceutical Preparations; Play; Progress Reports; Randomized; Randomized Controlled Clinical Trials; Rate; Reporting; Research; Research Personnel; Role; Science; Site; Substance Use Disorder; Testing; Universities; Viral Load result; Work; addiction; base; design; expectation; improved; member; prescription document; prescription procedure; programs; response; treatment program

DESCRIPTION (provided by applicant): This is a proposal for renewal of "Clinical Trials Network (CTN): Harvard University Northern New England Node," submitted in response to RFA-DA-07-001 "Announcement of a Limited Competition of the National Drug Abuse Treatment Clinical Trials Network (U10)." The Northern New England Node (NNEN) brings together research expertise, sophisticated community treatment programs (CTPs), and a wide variety of patients being treated in diverse settings and multiple levels of care. The Node is characterized by a partnership between academic researchers and community-based treatment providers throughout 5 New England states to design and implement addiction treatment studies in community-based treatment programs. The NNEN has demonstrated outstanding progress since entering the CTN in 2002, with a combination of scientific and administrative leadership and excellent trial performance. The NNEN is the Lead Node on a multi-site study of prescription opioid analgesic dependence treatment, and has played a major scientific leadership role in the development and implementation of two CTN studies of patients with substance use disorder and attention deficit hyperactivity disorder. Administrative leadership is exemplified by participation by NNEN members on the 4 key CTN national committees; the NNEN is the only Node to be represented on all of these committees. NNEN members have also been elected to chair several national committees and work groups, demonstrating their excellent reputation among their CTN colleagues. Trial performance has been exemplary: the NNEN has participated in more trials and randomized more participants than any other Node entering in 2002; and has randomized more than twice as many participants in the 2005-2006 Node Trial Performance Report than the average for a CTN Node. Moreover, according to the most recent NIDA Trial Progress Report, the NNEN is the only Node (other than the 2 new Nodes entering the CTN in 2005) to meet or exceed expectations on every performance indicator of every trial the Node has entered. NNEN CTPs have adopted a number of new evidence-based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the Northern New England Node in the funding period since September 2002. While the Node has made outstanding progress, the proposal also details a number of enhancements to strengthen the NNEN during the renewal period. During the next three years, the NNEN plans to continue to advance the mission of the CTN by implementing and testing state-of-the-art drug abuse treatment interventions, so that clinical programs will use the best treatments available and patients will receive the full benefit of the evolving science of addiction treatment.

描述(由申请人提供)：这是针对RFA-DA-07-001《国家药物滥用治疗临床试验网络(U10)有限竞赛公告》而提交的《临床试验网络(CTN)：哈佛大学新英格兰北部节点》的续展建议书。新英格兰北部节点(NNEN)汇集了研究专业知识、复杂的社区治疗计划(CTP)以及在不同环境和多层次护理下接受治疗的各种患者。该节点的特点是在新英格兰5个州的学术研究人员和社区治疗提供者之间建立合作伙伴关系，在社区治疗计划中设计和实施成瘾治疗研究。NNEN自2002年加入CTN以来取得了显著进展，科学和行政领导相结合，并取得了出色的试验业绩。NNEN是处方阿片类止痛剂依赖治疗多点研究的牵头节点，并在开发和实施两项针对物质使用障碍和注意缺陷多动障碍患者的CTN研究中发挥了重要的科学领导作用。NNEN成员参加了CTN的4个关键全国委员会，体现了行政领导能力；NNEN是在所有这些委员会中派代表的唯一节点。NENN成员还被选为几个国家委员会和工作组的主席，显示了他们在CTN同事中的良好声誉。试验表现堪称典范：NNEN参加试验的次数和随机化的参与者比2002年参加的任何其他节点都多；在2005-2006年的Node试验表现报告中，随机化的参与者人数是CTN节点平均水平的两倍多。此外，根据NIDA最新的试验进度报告，NNEN是唯一一个节点(2005年进入CTN的2个新节点除外)，在该节点参加的每项试验的每项性能指标上达到或超过预期。NNEN CTP采用了一些新的基于证据的做法，并在区域、国家和国际上传播关于这些做法的信息。这项提案突出了新英格兰北部节点自2002年9月以来在资助期内取得的成就。虽然Node取得了显著的进展，但该提案还详细说明了在续期期间加强NNEN的一些改进措施。在接下来的三年里，NNEN计划通过实施和测试最先进的药物滥用治疗干预措施来继续推进CTN的使命，以便临床项目将使用可用的最佳治疗方法，患者将从不断发展的成瘾治疗科学中充分受益。